This 1994 study describes an acute growth-hormone response to hexarelin in 12 healthy adult men. The same participants received placebo and three ascending active conditions. The reported hormone peaks and integrated responses were higher under the active conditions, but these laboratory findings do not establish improved growth, body composition, recovery, symptoms or long-term safety.[1][2]
This page is a source-limited critical summary. The publisher's public abstract is longer than the indexed PubMed abstract, which is explicitly truncated at 250 words. The full paper, original tables and figures, protocol and complete analysis were not available to this review. Accordingly, the page distinguishes reported findings from details that could not be verified.
Study at a glance
| Field | Supported description |
|---|---|
| Publication | Imbimbo and colleagues, European Journal of Clinical Pharmacology 46(5):421–425; June 1994 |
| Population | 12 healthy adult male volunteers |
| Design | Double-blind, placebo-controlled, repeated-participant physiology experiment |
| Sequence | Three ascending acute active conditions; placebo randomly inserted into the sequence |
| Research material | The study's defined synthetic hexarelin, examined in an intravenous research context |
| Main reported measurements | Plasma growth-hormone peak and area under the concentration–time curve from zero to 180 minutes |
| Time course | Peak around 30 minutes; return to baseline reported within 240 minutes |
| Unverified details | Endpoint-complete denominators, participant flow, paired analysis, missing-data handling, protocol history and detailed harms |
| Review boundary | Public publisher abstract/metadata and separately indexed official abstract, not a full-paper audit |
The historical route identifies the experiment; it is not administration guidance. No practical amounts or model-derived exposure recommendations are provided here.
Twelve participants, not four independent groups
The abstract describes the same 12 men receiving the active conditions and placebo. These are repeated observations within people, not four separate groups of 12 or 48 independent participants. Nor does the stated sample size prove that every person supplied complete measurements at every time point.[1][2]
Only placebo's position is described as randomly inserted. The active conditions ascended for safety, so the study should not be described as having fully randomized active-treatment order. The source does not let this review verify allocation concealment, the washout interval, masking success or adjustment for period and carryover effects.
Repeated-participant designs can reduce differences between people, but they also create dependence between observations. If results from the same person are analyzed as unrelated observations, uncertainty can be misrepresented. The abstract does not provide enough detail to determine how that dependence was handled here. These are questions for the full methods, not evidence that the investigators necessarily analyzed the study incorrectly.
Peak and integrated hormone responses
The following values are descriptive summaries reproduced from the accessible primary abstracts, not independently reconstructed participant data.[1][2]
| Study condition | Mean peak GH, ng/mL | GH AUC, zero to 180 minutes, micrograms·minute/mL |
|---|---|---|
| Placebo | 3.9 | 0.135 |
| Lowest active condition | 26.9 | 1.412 |
| Middle active condition | 52.3 | 2.918 |
| Highest active condition | 55.0 | 3.695 |
Peak concentration and area under the curve answer different questions. The peak describes the maximum concentration; AUC integrates concentration over a specified time window. Neither is a direct measure of tissue growth, physical performance or patient benefit.
The two upper mean peaks are close, but their AUC values differ more visibly. It would therefore be misleading to turn the peak pattern into a claim that the two conditions produced identical overall responses. Without a prespecified equivalence comparison and its uncertainty, similar averages are not proof of equivalence or an optimal exposure.
The reported AUC ends at 180 minutes. It should not be relabeled as a 240-minute AUC merely because the hormone response reportedly returned to baseline within that longer interval.
Response decline is not peptide elimination
The abstract describes a growth-hormone peak at about 30 minutes and decline toward baseline within 240 minutes, with an approximately 55-minute half-life for that response.[1][2] This is not a verified elimination half-life of hexarelin itself.
A drug concentration and the biological response it triggers are different measurements. Establishing peptide elimination would require appropriate drug measurements and analysis; the hormone-response summary alone does not supply them. It also cannot establish a repeat-use interval.
Similarly, return of circulating growth hormone to baseline does not prove that every biological effect has disappeared or that carryover was excluded before the next study occasion. That requires the actual study schedule and relevant supporting evidence.
What the fitted model adds, and does not add
The investigators report using logistic regression to estimate theoretical maximum responses and half-maximum parameters. Reported maxima were 55.1 ng/mL for peak GH and 3,936 ng·minute/mL for AUC.[1][2]
The model's AUC maximum uses nanograms, whereas the observed AUC values above use micrograms. The equivalent expression, 3.936 micrograms·minute/mL, is a unit conversion, not a separate measured result. Mixing those units would create a thousand-fold error.
These fitted maxima are not observed physiological ceilings in every person. With only three active conditions, the model's assumptions and uncertainty matter. The exposed text does not provide parameter confidence intervals, individual trajectories or sufficient model diagnostics for an independent robustness assessment. A fitted half-maximum is also not a clinical effectiveness or safety threshold.
Other hormones and clinical interpretation
The longer publisher abstract describes no change in glucose, luteinising hormone, follicle-stimulating hormone, thyroid-stimulating hormone or IGF-I, and slight increases in prolactin, cortisol and adrenocorticotropic hormone.[1] The shorter indexed abstract ends before these observations.
Those descriptions do not include the numerical contrasts, confidence intervals or complete tests needed to evaluate their precision. “No change” should not become a verified equivalence finding, and “slight” should not become a conclusion that an effect is clinically harmless. The additional hormone observations also caution against portraying the response as exclusively confined to GH.
Most importantly, an acute biomarker response is not itself evidence of a useful clinical effect. The material reviewed here supplies no demonstrated improvement in growth, strength, recovery, body composition or disease outcomes. This is a limit of the reviewed evidence, not an exhaustive claim about every measurement in the unread full paper. The surrogate-endpoint guide explains why the connection to benefit requires separate evidence.
Precision, missingness and analysis limits
The accessible abstracts provide means and model estimates but not a complete set of inferential comparisons, exact P values or confidence intervals. This summary therefore does not add significance labels or invent a minimum clinically important effect.
The endpoint hierarchy, prospective power calculation, analysis population, exclusions, within-participant covariance model and missing-data rules were not independently verified. An intention-to-treat or per-protocol label should not be supplied from the sample size alone. Missing uncertainty does not prove no effect; equally, a large-looking mean contrast does not settle its precision or freedom from bias.
Twelve selected participants provide a narrow basis for population inference. The observed response cannot simply be assigned to women, children, patients with endocrine disease or people with different concurrent treatments. The guide to confidence intervals and multiplicity separates effect size from statistical uncertainty.
Safety reporting is limited
The publisher abstract offers an overall favorable tolerability assessment for the participants.[1] It does not expose an event-level table, collection method, severity distribution, complete safety denominators or longer-term follow-up.
That summary is not a documented zero-event count. A small acute study cannot reliably characterize uncommon, delayed or cumulative risks, although it is not literally incapable of observing an uncommon event. Absence of detailed reporting in an abstract is also not proof that the full article contains no safety information.
The ascending sequence was described as a safety precaution. A design precaution and an observed safety result are different evidence. Neither the sequence nor the hormone-return time establishes safety for repeated use.
Affiliations, registration and material identity
The publisher lists authors at Mediolanum Farmaceutici's Medical Department in Milan, the Drug Research Unit at Guy's Hospital in London, and Europeptides in Argenteuil.[1] Affiliations are not a substitute for a funding statement, conflict disclosure, manufacturer specification or account of sponsor control. Those details were not independently verified; they are not asserted to be absent from the full paper.
No registration history or dated protocol was reviewed. The exposed sources do not supply a usable protocol-to-publication comparison, but this review did not conduct a registry search and does not establish that no registration or protocol exists. It also does not renew an earlier claim that no correction or retraction notice was displayed.
The reported peptide sequence is His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2.[1][2] A matching name cannot verify another material's sequence, stereochemistry, terminal amidation, salt form, purity, concentration, sterility, stability or formulation. This study is not an authentication of another preparation, a comparison of commercial products or a current regulatory-status determination.
Frequently asked questions
Were 48 people studied?
No. The study describes 12 men exposed to four conditions. Repeated observations do not create independent additional participants, and complete data at every endpoint were not verified.
Was the order fully randomized?
No such claim is supported. Placebo was randomly inserted, while active conditions ascended. The abstract does not establish a fully randomized active sequence or verified carryover control.
Did similar upper peaks establish an optimum?
No. Similar mean peaks are not an equivalence test, and the integrated hormone responses differed. A laboratory response pattern cannot by itself identify an exposure with the best clinical benefit–harm balance.
Does the 55-minute figure describe hexarelin's half-life?
It describes the reported GH-response decline. It is not a verified peptide-elimination estimate and should not be used to infer a repeat-use schedule.
Was muscle growth or recovery demonstrated?
Not by the evidence reviewed here. The reported acute hormone response does not demonstrate those outcomes; the complete paper was not available for an exhaustive endpoint audit.
Does favorable tolerability mean no adverse events?
No. The public abstract does not provide the event-level information needed to confirm a zero-event count or characterize longer-term risk.
Does a name match validate another hexarelin material?
No. Identity, composition and formulation require their own verification, and the findings remain limited to the experimental material and context.
Related methods and study records
Use how to read a research study for a structured appraisal, randomization, masking and controls for the design distinctions, and cell, animal and human evidence for limits on extrapolation. Return to Research Study Records for separately identified studies.
Primary sources and review scope
- Springer: public abstract, metadata and affiliations.
- PubMed identifier and indexed abstract: PMID 7957536.
- DOI identifier: 10.1007/BF00191904.
Editorial evidence review: September 3, 2026. This source-limited review used the exposed publisher abstract and separately indexed official abstract. It did not include the full paper, original table or figure images, a protocol/analysis-plan audit, a comprehensive notice search or independent specialist certification. Source access and article status can change. This page is educational, not medical advice or self-use guidance. Report a source or wording correction.